Literature DB >> 23873879

Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.

Allison L Mathes1, Romy B Christmann1, Giuseppina Stifano1, Alsya J Affandi2, Timothy R D J Radstake2, G Alessandra Farina1, Cristina Padilla1, Sarah McLaughlin1, Robert Lafyatis1.   

Abstract

OBJECTIVE: To characterise global chemokine expression in systemic sclerosis (SSc) skin in order to better understand the relationship between chemokine expression and vascular inflammation in this disease.
METHODS: We investigated chemokine mRNA expression in the skin through quantitative PCR analysis comparing patients with diffuse cutaneous (dcSSc) or limited cutaneous (lcSSc) disease with healthy controls. We tested correlations between the most regulated chemokines and vascular inflammation and macrophage recruitment. CCL19 expression was examined in human primary immune cells treated with innate immune activators.
RESULTS: The chemokines, CCL18, CCL19 and CXCL13, were upregulated in dcSSc skin, and CCL18 in lcSSc skin. Expression of CCL19 in dcSSc skin correlated with markers of vascular inflammation and macrophage recruitment. Immunofluorescence data showed CCL19 colocalisation with CD163 macrophages in dcSSc skin. In vitro studies on human primary cells demonstrated that CCL19 expression was induced after toll-like receptor activation of peripheral blood mononuclear cells and separated populations of CD14 monocytes.
CONCLUSIONS: CCL18, CCL19 and CXCL13-chemoattractants for macrophage and T cell recruitment-were three of six chemokines with the highest expression in dcSSc skin. Increased CCL19 expression in the skin suggests a role for CCL19 in the recruitment of immune cells to the peripheral tissue. Induction of CCL19 in macrophages but not structural cells indicates a role for skin-resident or recruited immune cells in perivascular inflammation. This study demonstrates that CCL19 is a sensitive marker for the perivascular inflammation and immune cell recruitment seen in dcSSc skin disease. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Chemokines; Inflammation; Systemic Sclerosis

Mesh:

Substances:

Year:  2013        PMID: 23873879      PMCID: PMC4076390          DOI: 10.1136/annrheumdis-2012-202814

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  57 in total

1.  Synergy-inducing chemokines enhance CCR2 ligand activities on monocytes.

Authors:  Katrin Kuscher; Gabriela Danelon; Samantha Paoletti; Luisa Stefano; Milena Schiraldi; Vibor Petkovic; Massimo Locati; Basil O Gerber; Mariagrazia Uguccioni
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

2.  Macrophages participate in lymphangiogenesis in idiopathic diffuse alveolar damage through CCL19-CCR7 signal.

Authors:  Masahiro Yamashita; Noriyuki Iwama; Fumiko Date; Naoko Shibata; Hiroshi Miki; Kohei Yamauchi; Takashi Sawai; Shinobu Sato; Tohru Takahashi; Masao Ono
Journal:  Hum Pathol       Date:  2009-06-21       Impact factor: 3.466

3.  Functional expression of the chemokine receptor CCR7 on fibroblast-like synoviocytes.

Authors:  H Brühl; M Mack; M Niedermeier; D Lochbaum; J Schölmerich; R H Straub
Journal:  Rheumatology (Oxford)       Date:  2008-10-04       Impact factor: 7.580

4.  A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.

Authors:  G Farina; D Lafyatis; R Lemaire; R Lafyatis
Journal:  Arthritis Rheum       Date:  2010-02

5.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.

Authors:  Michael R York; Taro Nagai; Alyson J Mangini; Raphaël Lemaire; Jean Maguire van Seventer; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2007-03

6.  B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

Authors:  Robert Lafyatis; Eugene Kissin; Michael York; Giuseppina Farina; Kerry Viger; Marvin J Fritzler; Peter A Merkel; Robert W Simms
Journal:  Arthritis Rheum       Date:  2009-02

7.  CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.

Authors:  Antje Prasse; Dmitri V Pechkovsky; Galen B Toews; Markus Schäfer; Stephan Eggeling; Corinna Ludwig; Martin Germann; Florian Kollert; Gernot Zissel; Joachim Müller-Quernheim
Journal:  Arthritis Rheum       Date:  2007-05

Review 8.  CCR7 and its ligands: balancing immunity and tolerance.

Authors:  Reinhold Förster; Ana Clara Davalos-Misslitz; Antal Rot
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

9.  Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.

Authors:  Jason W Bauer; Michelle Petri; Franak M Batliwalla; Thearith Koeuth; Joseph Wilson; Catherine Slattery; Angela Panoskaltsis-Mortari; Peter K Gregersen; Timothy W Behrens; Emily C Baechler
Journal:  Arthritis Rheum       Date:  2009-10

10.  Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin.

Authors:  Ralf J Ludwig; Katja Hardt; Max Hatting; Roxana Bistrian; Sandra Diehl; Heinfried H Radeke; Maurizio Podda; Michael P Schön; Roland Kaufmann; Reinhard Henschler; Josef M Pfeilschifter; Sentot Santoso; Wolf-Henning Boehncke
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

View more
  21 in total

Review 1.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

Review 2.  Update on macrophages and innate immunity in scleroderma.

Authors:  Jennifer J Chia; Theresa T Lu
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

Review 3.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

Review 4.  Cytokines in the immunopathology of systemic sclerosis.

Authors:  Jasmin Raja; Christopher Paul Denton
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

Review 5.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

Review 6.  Transforming growth factor β--at the centre of systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

Review 7.  Gene expression profiling offers insights into the role of innate immune signaling in SSc.

Authors:  Michael E Johnson; Patricia A Pioli; Michael L Whitfield
Journal:  Semin Immunopathol       Date:  2015-07-30       Impact factor: 9.623

8.  A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis.

Authors:  Lisa M Rice; Jessica Ziemek; Eric A Stratton; Sarah R McLaughlin; Cristina M Padilla; Allison L Mathes; Romy B Christmann; Giuseppina Stifano; Jeffrey L Browning; Michael L Whitfield; Robert F Spiera; Jessica K Gordon; Robert W Simms; Yuqing Zhang; Robert Lafyatis
Journal:  Arthritis Rheumatol       Date:  2015-11       Impact factor: 10.995

Review 9.  Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.

Authors:  Gabriela Kania; Michal Rudnik; Oliver Distler
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

10.  Expansion of Fcγ Receptor IIIa-Positive Macrophages, Ficolin 1-Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis.

Authors:  Dan Xue; Tracy Tabib; Christina Morse; Yi Yang; Robyn T Domsic; Dinesh Khanna; Robert Lafyatis
Journal:  Arthritis Rheumatol       Date:  2022-01-18       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.